Selective organ-targeting lipid nanoparticle platform for genetic medicine delivery beyond the liver.
SORT LNP Platform is ReCode Therapeutics’ selective organ targeting technology for genetic medicines. Its lipid nanoparticles deliver nucleic acid payloads to specific organs and tissues, with inhaled delivery focused on lung cells.
The platform supports ReCode’s mRNA and gene-correction programs for cystic fibrosis and primary ciliary dyskinesia. Biopharma partners can use its inhaled delivery technology to develop additional genetic medicine programs beyond ReCode’s pipeline.
Mana.bio
AI LNP Design Platform, Mina
mana.bio
Copernicus Therapeutics
STELLAR
copernicustherapeutics.com
Artan Bio
tRNA Therapy Platform
artan.bio
| Attribute | SORT LNP Platform | AI LNP Design Platform, Mina | STELLAR | tRNA Therapy Platform | |
|---|---|---|---|---|---|
| Provider | | | | | |
| Founded | 2015 | 2021 | 1995 | — | |
| Sells To | Enterprise, Small Business | Enterprise | Enterprise | — | |
| Pricing Model | Software | Recurring, Software | — | — | |
| Ownership | Venture-backed | Venture-backed | Private | Private |
Provider
Founded 2015
Sells To Enterprise, Small Business
Pricing Model Software
Ownership Venture-backed
Provider
Founded 2021
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Venture-backed
Provider
Founded 1995
Sells To Enterprise
Pricing Model —
Ownership Private
Provider
Founded —
Sells To —
Pricing Model —
Ownership Private
Clinically validated lipid nanoparticle delivery systems for nucleic acid therapeutics.
A programmable RNA editing platform developing therapies for genetic disease.
Biomolecular RNA delivery platform targeting specific cells and organs including across the blood-brain barrier.
Aptamer delivery platform for tissue-specific delivery of RNA payloads including siRNA, ASO, and LNPs.
Antibody-oligonucleotide conjugate platform delivering siRNA and PMO payloads to muscle, cardiac, and immune cells.
Clinically validated lipid nanoparticle delivery systems for nucleic acid therapeutics.
A programmable RNA editing platform developing therapies for genetic disease.
Biomolecular RNA delivery platform targeting specific cells and organs including across the blood-brain barrier.
Aptamer delivery platform for tissue-specific delivery of RNA payloads including siRNA, ASO, and LNPs.
Antibody-oligonucleotide conjugate platform delivering siRNA and PMO payloads to muscle, cardiac, and immune cells.
Nonviral ultrasound-mediated platform delivering DNA and RNA payloads to targeted tissues using microbubble enhancing agents.